News | September 28, 2021
Bal Pharma ramps up API capacity of Gliclazide
In terms of volume, the company commands a market share 25 per cent globally for Gliclazide, as per the IQVIA report
In terms of volume, the company commands a market share 25 per cent globally for Gliclazide, as per the IQVIA report
Post normalisation of high growth months of April and May this year the average IPM growth from June to August this year stood at 15.2 % YoY : Ind-Ra reports
The purchaser is a part of the portfolio companies of PE firm True North. The said transaction is not a related party transaction.
_256_384.jpg)
CLSA, a capital market and investment group organised an Investors’ Forum where five Indian pharma companies participated. Excerpts from the report
Barbara Engelhardt moves her computational and statistics lab to Gladstone
Godrej and Boyce and Isgec Engineering have confirmed receiving the orders
The amalgamation is expected to bring in a lot of synergies in terms of operational efficiency and productivity for the combined entity
The trial will evaluate the efficacy of psilocybin in Short-lasting Unilateral Neuralgiform Headache Attacks (SUNHA). The data is expected in early 2022
It has been built at a cost of Rs 19.5 crores through internal accruals of the Malabar Institute of Medical Sciences (MIMS)
One batch has 11.4 million units of Naproxen tablets out of which 0.9 million units that were released into the market were recalled
Subscribe To Our Newsletter & Stay Updated
